FOY 251 HCl is a Camostat metabolite with anti-proteolytic activity, and acts as a proteinase inhibitor.

Bemnifosbuvir hemisulfate (RG-6422; AT-527), the hemisulfate salt of AT-511, is a guanosine nucleotide prodrug and orally bioactive HCV viral replication inhibitor.

Nafamostat (formerly also known as FUT-175) is a novel and synthetic serine protease inhibitor, which is used as an anticoagulant during hemodialysis.

Paquinimod (ABR‑215757; ABR215757) is a novel and potent S100A9 inhibitor that can prevent S100A9 binding to TLR-4 (Toll like receptor-4).

PF-00835231 (PF-835231) is a potent 3CLpro [main protease (Mpro)] inhibitor developed by Pfizer for COVID-19 treatment.

Nirmatrelvir (PF-07321332), the key component of Paxlovid [Nirmatrelvir (PF-07321332) and ritonavir] which is newly approved COVID-19 oral antiviral drug, is an orally bioavailable 3C-like protease (3CLPRO) inhibitor with potent antiviral effects against SARS-CoV-2 virus and COVID-19. On December 22, 2021, FDA issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, […]

VV-116 (also known as VV116, JT-001) is a novel, potent and orally administered anti-SARS-CoV-2 nucleoside drug candidate (IC50 = 0.67±0.24 μM) acting as a viral RNA-dependent RNA polymerase (RdRp) inhibitor and is under investigation for COVID-19 treatment in China.

EIDD-1931 (EIDD1931; Beta-d-N4-hydroxycytidine; NHC) is a novel and potent ribonucleoside analog with antiviral activity.

Molnupiravir (EIDD-2801; MK4482; prodrug-EIDD1931; MK-4482; trade name Lagevrio) is a novel, potent and orally bioavailable prodrug of the ribonucleoside analog EIDD-1931 with a broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as COVID-19, SARS-CoV-2, MERS-CoV, SARS-CoV.

Aviptadil (Vasoactive Intestinal Peptide) is a novel analog of vasoactive intestinal polypeptide (VIP) with the potential for the treatment of erectile dysfunction.